Edoxaban in venous thromboembolism and stroke prevention: an appraisal

References

• LipGYLaneDAStroke prevention in atrial fibrillation: a systematic reviewJAMA2015313191950196225988464
   PubMed Web of Science ®Google Scholar
• CammAJLipGYDe CaterinaR2012 Focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm AssociationEur Heart J201233212719274722922413
   PubMed Web of Science ®Google Scholar
• KearonCAklEAComerotaAJAntithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest20121412 Supple419Se494S22315268
   PubMed Web of Science ®Google Scholar
• MozaffarianDBenjaminEJGoASHeart disease and stroke statistics – 2015 update: a report from the American Heart AssociationCirculation20141314e29e32225520374
   PubMed Web of Science ®Google Scholar
• HeitJAEpidemiology of venous thromboembolismNat Rev Cardiol201512846447426076949
   PubMed Web of Science ®Google Scholar
• De CaterinaRHustedSWallentinLVitamin K antagonists in heart disease: current status and perspectives (section III)Thromb Haemost201311061087110724226379
   PubMed Web of Science ®Google Scholar
• SjögrenVGrzymala-LubanskiBRenlundHSafety and efficacy of well managed warfarin: a report from the Swedish quality register AuriculaThromb Haemost201511361370137725716771
   PubMed Web of Science ®Google Scholar
• GallegoPRoldanVMarínFCessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillationThromb Haemost201311061189119824096615
   PubMed Web of Science ®Google Scholar
• ApostolakisSSullivanRMOlshanskyBLipGYFactors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 scoreChest201314451555156323669885
   PubMed Web of Science ®Google Scholar
• ProiettiMLipGYSimple decision-making between a vitamin K antagonist and a non-vitamin K antagonist oral anticoagulant: using the SAMe-TT2R2 scoreEur Heart J Cardiovasc Pharmacother201513150152
   PubMedGoogle Scholar
• Ruiz-OrtizMBertomeuVCequierAMarínFAnguitaMValidation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonistsThromb Haemost2015114469570126054407
   PubMed Web of Science ®Google Scholar
• FauchierLPoliDOlshanskyBThe SAMe-TT2R2 score and quality of anticoagulation in AF: can we predict which patient benefits from anticoagulation?Thromb Haemost2015114465765926246340
   PubMed Web of Science ®Google Scholar
• HustedSde CaterinaRAndreottiFNon-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novelThromb Haemost2014111578178224658395
   PubMed Web of Science ®Google Scholar
• DzeshkaMSLipGYNon-vitamin K oral anticoagulants in atrial fibrillation: where are we now?Trends Cardiovasc Med201525431533625440108
   PubMed Web of Science ®Google Scholar
• GrangerCBAlexanderJHMcMurrayJJApixaban versus warfarin in patients with atrial fibrillationN Engl J Med20113651198199221870978
   PubMed Web of Science ®Google Scholar
• ProvidênciaRGroveELHustedSBarraSBovedaSMoraisJA meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimensThromb Res201413461253126425457584
   PubMed Web of Science ®Google Scholar
• YehCHGrossPLWeitzJIEvolving use of new oral anticoagulants for treatment of venous thromboembolismBlood201412471020102824923298
   PubMed Web of Science ®Google Scholar
• DentaliFRivaNCrowtherMTurpieAGLipGYAgenoWEfficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literatureCirculation2012126202381239123071159
   PubMed Web of Science ®Google Scholar
• CaldeiraDRodriguesFBBarraMNon-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysisHeart2015101151204121126037103
   PubMed Web of Science ®Google Scholar
• GiuglianoRPRuffCTBraunwaldEEdoxaban versus warfarin in patients with atrial fibrillationN Engl J Med2013369222093210424251359
   PubMed Web of Science ®Google Scholar
• WeitzJIEikelboomJIncorporating edoxaban into the choice of anticoagulants for atrial fibrillationThromb Haemost2015115225727026466666
   PubMed Web of Science ®Google Scholar
• FurugohriTIsobeKHondaYDU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profilesJ Thromb Haemost2008691542154918624979
   PubMed Web of Science ®Google Scholar
• ZafarMUVorchheimerDAGaztanagaJAntithrombotic effects of factor Xa inhibition with DU-176b: phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamberThromb Haemost200798488388817938815
   PubMed Web of Science ®Google Scholar
• DouxfilsJChatelainBChatelainCDognéJMMullierFEdoxaban: impact on routine and specific coagulation assays – a practical laboratory guideThromb Haemost2015115236838126510969
   PubMed Web of Science ®Google Scholar
• OgataKMendell-HararyJTachibanaMClinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteersJ Clin Pharmacol201050774375320081065
   PubMed Web of Science ®Google Scholar
• LipGYAgnelliGEdoxaban: a focused review of its clinical pharmacologyEur Heart J201435281844185524810388
   PubMed Web of Science ®Google Scholar
• ParasrampuriaDAMarburyTMatsushimaNPharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysisThromb Haemost2015113471972725566930
   PubMed Web of Science ®Google Scholar
• HylekEMKoDCoveCLGaps in translation from trials to practice: non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillationThromb Haemost2014111578378824573511
   PubMed Web of Science ®Google Scholar
• ChanNCPaikinJSHirshJLauwMNEikelboomJWGinsbergJSNew oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusionsThromb Haemost2014111579880724553904
   PubMed Web of Science ®Google Scholar
• ConnollySJEzekowitzMDYusufSDabigatran versus warfarin in patients with atrial fibrillationN Engl J Med2009361121139115119717844
   PubMed Web of Science ®Google Scholar
• PatelMRMahaffeyKWGargJRivaroxaban versus warfarin in nonvalvular atrial fibrillationN Engl J Med20113651088389121830957
   PubMed Web of Science ®Google Scholar
• RuffCTGiuglianoRPAntmanEMEvaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48)Am Heart J2010160463564120934556
   PubMed Web of Science ®Google Scholar
• WeitzJIConnollySJPatelIRandomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillationThromb Haemost2010104363364120694273
   PubMed Web of Science ®Google Scholar
• YamashitaTKoretsuneYYasakaMRandomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillationCirc J20127681840184722664798
   PubMed Web of Science ®Google Scholar
• ChenJZhuangXLongMSuCWangLEfficacy and safety of edoxaban in nonvalvular atrial fibrillation: a meta-analysis of randomized controlled trialsJ Stroke Cerebrovasc Dis201524122710271926324517
   PubMed Web of Science ®Google Scholar
• RuffCTGiuglianoRPBraunwaldEAssociation between edoxaban dose, concentration, anti-factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trialLancet201538599842288229525769361
   PubMed Web of Science ®Google Scholar
• BlannADBanerjeeALaneDATorp-PedersenCLipGYNet clinical benefit of edoxaban versus no treatment in a “real world” atrial fibrillation population: a modelling analysis based on a nationwide cohort studyInt J Cardiol201520169369826379097
   PubMed Web of Science ®Google Scholar
• LipGYMitchellSALiuXRelative efficacy and safety of non-vitamin K oral anticoagulants for non-valvular atrial fibrillation: network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroupsInt J Cardiol2015204889426655548
   PubMed Web of Science ®Google Scholar
• SkjøthFLarsenTBRasmussenLHLipGYEfficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: an indirect comparison analysisThromb Haemost2014111598198824577485
   PubMed Web of Science ®Google Scholar
• BlannADSkjøthFRasmussenLHLarsenTBLipGYEdoxaban versus placebo, aspirin, or aspirin plus clopidogrel for stroke prevention in atrial fibrillation: an indirect comparison analysisThromb Haemost2015114240340926062437
   PubMed Web of Science ®Google Scholar
• ShieldsAMLipGYChoosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillationJ Intern Med2015278111825758241
   PubMed Web of Science ®Google Scholar
• LipGYMerinoJEzekowitzMA prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) studyAm Heart J20151695597e5604.e525965706
   PubMed Web of Science ®Google Scholar
• PrandoniPTreatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populationsThromb Res2014134222723324875390
   PubMed Web of Science ®Google Scholar
• HirschlMKundiMNew oral anticoagulants in the treatment of acute venous thromboembolism – a systematic review with indirect comparisonsVasa201443535336425147012
   PubMed Web of Science ®Google Scholar
• RaskobGBüllerHPrinsMEdoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study – methodological implications for clinical trialsJ Thromb Haemost20131171287129423574579
   PubMed Web of Science ®Google Scholar
• BüllerHRDécoususHGrossoMAEdoxaban versus warfarin for the treatment of symptomatic venous thromboembolismN Engl J Med2013369151406141523991658
   PubMed Web of Science ®Google Scholar
• BounameauxHCammAJEdoxaban: an update on the new oral direct factor Xa inhibitorDrugs201474111209123125034361
   PubMed Web of Science ®Google Scholar
• van EsNDi NisioMBlekerSMEdoxaban for treatment of venous thromboembolism in patients with cancerThromb Haemost201511461268127626271200
   PubMed Web of Science ®Google Scholar
• NakamuraMWangYQWangCEfficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trialJ Thromb Haemost20151391606161426179767
   PubMed Web of Science ®Google Scholar
• ProiettiMLipGYAntidotes to non-vitamin K oral anticoagulants: necessary or not?Expert Opin Pharmacother201516111573157626077323
   PubMed Web of Science ®Google Scholar
• NiessnerATamargoJMoraisJReversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management – a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on ThrombosisEur Heart J Epub20151224
   Web of Science ®Google Scholar
• GlundSMoschettiVNorrisSA randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatranThromb Haemost2015113594395125789661
   PubMed Web of Science ®Google Scholar
• PollackCVReillyPABernsteinRDesign and rationale for RE-VERSE AD: a phase 3 study of idarucizumab, a specific reversal agent for dabigatranThromb Haemost2015114119820526020620
   PubMed Web of Science ®Google Scholar
• PollackCVReillyPAEikelboomJIdarucizumab for dabigatran reversalN Engl J Med2015373651152026095746
   PubMed Web of Science ®Google Scholar
• SiegalDMCurnutteJTConnollySJAndexanet alfa for the reversal of factor Xa inhibitor activityN Engl J Med2015373252413242426559317
   PubMed Web of Science ®Google Scholar
• HankeyGJUnanswered questions and research priorities to optimise stroke prevention in atrial fibrillation with the new oral anticoagulantsThromb Haemost2014111580881624285341
   PubMed Web of Science ®Google Scholar
• WangKLLipGYLinSJChiangCENon-vitamin K antagonist oral anticoagulants for stroke prevention in Asian patients with nonvalvular atrial fibrillation: meta-analysisStroke20154692555256126304863
   PubMed Web of Science ®Google Scholar